Literature DB >> 24136572

Liver failure following antituberculosis (ATT) chemotherapy for presumed tuberculous uveitis.

M J Wakefield1, P Kumar1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24136572      PMCID： PMC3890757          DOI： 10.1038/eye.2013.226

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  6 in total

1.  Isoniazid, rifampin, and hepatotoxicity.

Authors:  P R Gangadharam
Journal:  Am Rev Respir Dis       Date:  1986-06

2.  Clinical presentation, treatment, and outcomes in presumed intraocular tuberculosis: experience from Newcastle upon Tyne, UK.

Authors:  K Manousaridis; E Ong; C Stenton; R Gupta; A C Browning; R Pandit
Journal:  Eye (Lond)       Date:  2013-02-22       Impact factor: 3.775

3.  American Thoracic Society. Medical Section of the American Lung Association. Guidelines for short-course tuberculosis chemotherapy.

Authors:  M D Iseman; R Albert; M Locks; J Raleigh; F Sutton; L S Farer
Journal:  Am Rev Respir Dis       Date:  1980-03

4.  Presumed tuberculous uveitis: diagnosis, management, and outcome.

Authors:  C Sanghvi; C Bell; M Woodhead; C Hardy; N Jones
Journal:  Eye (Lond)       Date:  2011-02-04       Impact factor: 3.775

5.  Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide.

Authors:  R Parthasarathy; G R Sarma; B Janardhanam; P Ramachandran; T Santha; S Sivasubramanian; P R Somasundaram; S P Tripathy
Journal:  Tubercle       Date:  1986-06

6.  A controlled trial of six months chemotherapy in pulmonary tuberculosis. First Report: results during chemotherapy. British Thoracic Association.

Authors: 
Journal:  Br J Dis Chest       Date:  1981-04
  6 in total
  1 in total

1.  Reply to Wakefield and Kumar.

Authors:  K Manousaridis; E Ong; C Stenton; R Gupta; A C Browning; R Pandit
Journal:  Eye (Lond)       Date:  2013-10-18       Impact factor: 3.775
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.